Evommune, Inc. (EVMN)
| Market Cap | 819.63M |
| Revenue (ttm) | 13.00M |
| Net Income (ttm) | -62.82M |
| Shares Out | 31.52M |
| EPS (ttm) | -40.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 324,141 |
| Open | 27.01 |
| Previous Close | 26.63 |
| Day's Range | 25.26 - 27.60 |
| 52-Week Range | 13.89 - 33.20 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 44.17 (+69.89%) |
| Earnings Date | Jun 10, 2026 |
About EVMN
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for EVMN stock is "Strong Buy." The 12-month stock price target is $44.17, which is an increase of 69.89% from the latest price.
News
Evommune Announces $125 Million Private Placement
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial
Evommune, Inc. (NASDAQ: EVMN) shares are trading lower on Thursday on profit-taking after the stock soared around 70% on Wednesday.
Evommune's Stock Surges On Strong Results For New Eczema Drug
The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/kg on day 1 and day 28 (n=48 active, n=22 placebo) over 12 weeks.
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
PALO ALTO, Calif.--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory ...
Evommune Announces Pricing of its Initial Public Offering
PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory dis...
Evommune Announces Commencement of Initial Public Offering
PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory di...
Evommune Aims For IPO In Bifurcated Biopharma Market
Evommune, Inc. is seeking to raise $100 million in an IPO to advance its pipeline of inflammatory disease treatments. EVMN's lead candidate, EVO756, is in Phase 2 trials for chronic spontaneous urtica...
Evommune files for IPO to advance immune drug work
The company has a pair of drugs in mid-stage testing for urticarias and atopic dermatitis.
Evommune IPO Registration Document (S-1)
Evommune has filed to go public with an IPO on the New York Stock Exchange (NYSE)
Chronic inflammatory disease biotech Evommune files for a $100 million IPO
Evommune, a Phase 2 biotech developing therapies for chronic inflammatory diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.